B A C K G R O U N D Description of the condition
Constipation is among the most common gastrointestinal disorders and a major public health problem (Anderson 2000) . It is estimated that about 15% of adult population in western countries suffer from constipation. The overall prevalence in North America ranges from 4% to 18% with predominance among females. It has been shown that constipation affects 5% of males and 15% of female population (Talley 1999) . The etiology of constipation remains largely unknown. The variety of symptoms and risk factors associated with constipation suggest that its etiology is likely to be multifactorial. Although epidemiologic studies cannot establish etiologic relationships, consistent epidemiologic distributions may suggest potential causative risk factors. Constipation does not have one consistently used definition. When using the term the lay public or health care professional may be referring to several difficult to quantify variables: bowel movement frequency, stool size or consistency, and symptoms such as a feeling of incomplete evacuation. Stool frequency is often used to describe constipation however using stool frequency to define constipation is not well established . The Rome criteria have been applied to clinical practice to identify patients with constipation. The Rome III criteria define functional constipation as a complex of at least two symptoms for the last 3 months with symptom onset at least 6 months prior to diagnosis. These symptoms include infrequent bowel movements (less than three per week), straining, lumpy or hard stools or a subjective sensation of incomplete bowel evacuation or anorectal obstruction or blockage, or manual maneuvers to enable defecation during at least 25% of bowel movements (Longstreth 2006) . Constipation may be associated with a number of different diseases or conditions. The known etiologies of constipation include mechanical obstruction, metabolic disturbances, neurologic disorders, and medication adverse effects. A large proportion of pa-tients with constipation do not have a known cause and suffer from idiopathic or primary constipation. Primary constipation is further classified into normal transit, slow transit and dyssynergic constipation. Secondary constipation may be associated with endocrine, metabolic, or neurologic diseases. It is also commonly associated with chronic laxative use and medication such as opioid analgesics, ferrous compounds and psychoactive drugs (Bassotti 2004) . Untreated chronic constipation can have serious medical consequences. Studies have reported that constipation can lead to pudendal nerve damage, resulting in fecal incontinence and rectal prolapse. Chronic constipation has also been associated with urinary tract infections and haemorrhoids (Mostafa 2003) . A study conducted on more than 100,000 patients revealed that patients with chronic constipation were 5 times more likely to develop intestinal impaction and anal fissures (Singh 2005 
Description of the intervention
Management of normal and slow transit chronic constipation includes patient education, lifestyle modification (increase exercise, hydration), behavior modification, dietary changes (dietary fiber), and bulk laxative therapy (psyllium or methylcellulose). There is a dose response between fiber intake, water intake, and fecal output. The recommended amount of dietary fiber is 20 to 35 g/day (Marlett 2002). However, fiber may increase bloating, distention and flatulence leading to poor compliance (estimated to be as low as 50%). Bulk forming laxatives include psyllium seed, methylcellulose, and calcium polycarbophil.
How the intervention might work
Bulk forming laxatives are natural or synthetic polysaccharides or cellulose derivatives that primarily exert their laxative effect by absorbing water and increasing fecal mass. These laxatives are effective in increasing the frequency and softening the consistency of stool with a minimum of adverse effects. Fiber and bulking agents including bran, methylcellulose, calcium polycarbophil and psyllium are commonly used laxatives (Brandt 2005) . Psyllium is a soluble fiber. It absorbs water in the intestine to form a viscous liquid which promotes peristalsis and reduce transit time. The daily recommended dose for constipation in adults is 10 to 15 grams per day in divided doses (Johanson 2007) . The onset of action ranges from 12 to 72 hours. Reported adverse effects of psyllium include: abdominal bloating, flatulence and cramps ( Gillespie 1992; Uehleke 2008; Wald 2008) . The laxative effect of wheat bran has been attributed to stimulation of bacterial growth and to retention of water by the fiber matrix. Methylcellulose absorbs water and expands in the intestine (known as peristalsis) which usually results in a bowel movement within 12 to 24 hours. Calcium polycarbophil also increases the bulk in stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass (Eherer 1993).
Why it is important to do this review
Chronic constipation is often under treated as many people perceive it as a temporary and personal problem that requires no medical attention. A random population-based survey in the United States indicates that only 26% of the patients seek medical care for constipation (Stewart 1999) . However, many studies have reported a high rate of compliance to fiber bulking agents (Levin 1990; Ramkumar 2005; Johanson 2007 ) compared to other synthetic drug treatment regimens, as the desire to take a natural supplement that is relatively cheap and easily available is appealing for patients. A systematic review of the efficacy and safety of fiber and bulking agents for the treatment of chronic constipation is required to evaluate all available evidence based information about this commonly used natural product.
O B J E C T I V E S
The primary objective is to evaluate the efficacy and safety of fiber and bulking agents for the treatment of chronic constipation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of fiber or bulking agent treatment for chronic constipation will be considered for inclusion.
Types of participants
Subjects of any age with symptoms of chronic constipation as defined by the included studies will be considered for inclusion.
Types of interventions
Interventions that involve fiber or bulking agents for the treatment of chronic constipation compared to placebo or any other active treatment will be considered for inclusion.
Types of outcome measures Primary outcomes
The primary outcomes will include:
• The proportion of patients with improvement in stool frequency as defined by the included studies; and
• The proportion of patients with global improvement in symptoms.
Secondary outcomes
Secondary outcomes will include:
• The proportion of patients experiencing three or more spontaneous bowel movements per week;
• Proportion of patients achieving bowel evacuation at defecation;
• Proportion of patients with bowel movements of normal consistency;
• Proportion of patients with relief of abdominal pain; • Quality of life; and • Adverse events including: the proportion of patients who experienced any adverse event, serious adverse events, and withdrawal due to adverse events.
Search methods for identification of studies
We will identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).
Electronic searches
The following electronic databases will be searched irrespective of language and publication status. Searches will be restricted to human participants.
• The Central Register of Controlled Trials (CENTRAL)The Cochrane Library The search terms will be combined with the highly sensitive search strategy through MEDLINE and CENTRAL. We will also search databases such as, Biological Abstracts and Web of Science. We will search for ongoing trials on : 'CurrentControlled Trials' registered at (www.controlled-trials.com -with links to other databases of ongoing trials) and ClinicalTrials.gov (http: //clinicaltrials.gov/). If additional key words of relevance are detected during any of the electronic or other searches we will modify the electronic search. All duplicate studies will be removed.
Searching other resources
Conference Proceedings for Digestive Disease Week (DDW) and United European Gastroentrology Week (UEGW) will be searched. The European Crohn's and Colitis Organisation (ECCO) conference abstract database and the IBD/FBD group specialized trials register will also be searched. We will not impose any language or publication restrictions. We will also search related conference proceedings for relevant abstracts. Moreover, we will contact organisations and researchers in the field and pharmaceutical companies for information on unpublished and ongoing trials. We will also check the reference lists of all trials identified by the above methods for additional studies.
Data collection and analysis

Selection of studies
Three review authors (KN, BA, SA) will independently assess all the potential studies identified as a result of the search strategy for inclusion based on the inclusion criteria described above. We will resolve any disagreement through discussion and, if required, we will consult the subject experts (WQ, SH).
Data extraction and management
We will design a data extraction form. Three review authors (KN, BA, SA) will independently extract the data using the agreed upon form. We will resolve discrepancies through discussion and, if required, we will consult the subject experts (WQ, SH). We will enter the data into the ReviewManager software (Revman 2011) and check for accuracy.
Assessment of risk of bias in included studies
Three review authors (KN, BA, SA) will independently assess the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a). We will resolve any disagreement by discussion with the subject experts (WQ, SH). The following criteria will be assessed:
• was the allocation sequence adequately generated?
• was the allocation adequately concealed?
• was knowledge of the allocated intervention adequately prevented during the study?
• were incomplete outcome data adequately addressed?
• were reports of the study free of suggestion of selective outcome reporting?
• was the study apparently free of other problems that could put it at a high risk of bias? A judgement of 'Yes' indicates low risk of bias, 'No' indicates high risk of bias and 'Unclear' indicates unclear or unknown risk of bias. Interrater agreement for key bias indicators (e.g. allocation concealment, incomplete outcome data) will be calculated using the kappa statistic (Cohen 1960) . In cases of disagreement, members of the research team will be consulted and a judgement will be made based on consensus. We will produce a risk of bias graph and risk of bias summary figure. Primary analyses for the review will be conducted including only those trials judged to be of 'low' risk of bias, considering all domains analysed. Domains relating to randomisation (sequence generation and allocation concealment) and blinding of participants, personnel and outcome assessors are likely to have the largest impact on bias in experimental studies. If adequate data are available, we will assess the impact of individual bias domains on study results. A sensitivity analysis including all studies will be performed to determine the impact that potentially high risk of bias studies may have had on the conclusions of the review.
Measures of treatment effect
Dichotomous outcomes will be expressed as risk ratio (RR) with 95% confidence intervals (CI). Continuous outcomes will be expressed as differences in means (MD) with 95% CI.
Unit of analysis issues
If any trials have multiple treatment groups, the 'shared' comparison group will be divided into the number of treatment groups and comparisons between each treatment group and the split comparison group will be treated as independent comparisons. Cross-over trials will be included if data from the first period are available.
Dealing with missing data
If feasible, we will obtain relevant missing data from authors, and carefully perform evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat (ITT), as-treated and per-protocol (PP) populations. We will investigate attrition rates, for example drop-outs, losses to follow up and withdrawals and critically appraise issues of missing data and imputation methods (for example last-observation-carried-forward (LOCF)).
Assessment of heterogeneity
We will measure heterogeneity among the trials by calculating the I 2 statistic (Higgins 2002; Higgins 2003) , which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis. If the I 2 statistic exceeds 50%, and the P value for the Chi 2 statistic is less than or equal to 0.1, and visual inspection of the forest plots is indicative, then we will consider heterogeneity to be substantial. When heterogeneity is found, we will attempt to determine potential reasons for it by examining individual study and subgroup characteristics (Higgins 2011b).
Assessment of reporting biases
If there are an appropriate number of studies we will use funnel plots to assess for the potential existence of small study bias. There are a number of explanations for the asymmetry of a funnel plot (Sterne 2001) and we will carefully interpret results (Lau 2006).
Data synthesis
Data will be pooled for meta-analysis if patients, interventions and outcomes are comparable (based on author consensus). A fixedeffect model will be used to pool data in the absence of heterogeneity. A random-effects model will be used to pool data when moderate heterogeneity is identified, Data will not be pooled for meta-analysis in cases where substantial heterogeneity is identified.
